http://www.broadcastmed.com/ http://www.broadcastmed.com/dermatology/8161/news/are-new-therapies-on-the-horizon-for-painful-skin-condition UCSF Health leads multi-center study of chronic inflammation of the skin that affects women and people of color disproportionately. http://www.broadcastmed.com/dermatology/8161/news/are-new-therapies-on-the-horizon-for-painful-skin-condition Mon, 19 Feb 2024 08:00:00 EST http://www.broadcastmed.com/dermatology/5225/news/fast-facts-on-precision-medicine-personalizing-care-for-scleroderma-an-autoimmune-disease The autoimmune disease scleroderma 鈥� which involves hardening of the skin 鈥� can affect multiple organs, from the heart to the lungs to the gastrointestinal tract and more. Rheumatologists who treat patients with the condition have to factor in multiple test results and characteristics to determine the best treatment decisions. But a new precision medicine program in use at Johns Hopkins has the power to help. http://www.broadcastmed.com/dermatology/5225/news/fast-facts-on-precision-medicine-personalizing-care-for-scleroderma-an-autoimmune-disease Mon, 20 Nov 2023 22:22:00 EST http://www.broadcastmed.com/dermatology/3593/news/mount-sinai-awarded-prestigious-1-3-million-grant-to-expand-research-training-program-in-skin-biology The research training program in Systems Skin Biology will take a multidisciplinary approach in teaching scientists to holistically understand human physiology, health, and disease. http://www.broadcastmed.com/dermatology/3593/news/mount-sinai-awarded-prestigious-1-3-million-grant-to-expand-research-training-program-in-skin-biology Mon, 10 Apr 2023 09:00:00 EST http://www.broadcastmed.com/dermatology/3593/news/new-treatment-for-moderate-to-severe-atopic-dermatitis-shows-promising-long-term-results Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab鈥攁 novel, patient-tailored monoclonal antibody therapy鈥攕howed promising results both while taking the drug and up to 20 weeks after the therapy was stopped. http://www.broadcastmed.com/dermatology/3593/news/new-treatment-for-moderate-to-severe-atopic-dermatitis-shows-promising-long-term-results Wed, 14 Dec 2022 09:00:00 EST http://www.broadcastmed.com/infectiousdiseases/4561/news/collateral-damage-car-t-covid-and-the-cytokine-storm-advances-at-penn-medicine-and-the-abramson-cancer-center In short, cytokine storm involves an immune response that causes collateral damage, which may be greater than the immediate benefit of the immune response. http://www.broadcastmed.com/infectiousdiseases/4561/news/collateral-damage-car-t-covid-and-the-cytokine-storm-advances-at-penn-medicine-and-the-abramson-cancer-center Wed, 18 Aug 2021 11:02:00 EST http://www.broadcastmed.com/neurology/1106/news/simple-skin-test-can-confirm-parkinson-s-diagnosis Patients suspected of having Parkinson鈥檚 disease can now have their diagnosis confirmed with a simple skin test available at Marcus Neuroscience Institute in Boca Raton. http://www.broadcastmed.com/neurology/1106/news/simple-skin-test-can-confirm-parkinson-s-diagnosis Thu, 29 Jul 2021 15:33:00 EST http://www.broadcastmed.com/cancer/9753/news/roswell-park-experts-share-insights-on-diagnosis-and-treatment-of-head/neck-cancers-at-ahns-2021 With the international community of experts in head-and-neck cancers gathering virtually to share new ideas and treatment strategies at the American Head & Neck Society (AHNS) 10th International Conference on Head and Neck Cancer, underway now, Roswell Park Comprehensive Cancer Center teams are presenting new research on both the basic science supporting new treatments as well as opportunities to improve the early and accurate diagnosis of thyroid cancer and other head/neck malignancies. http://www.broadcastmed.com/cancer/9753/news/roswell-park-experts-share-insights-on-diagnosis-and-treatment-of-head/neck-cancers-at-ahns-2021 Mon, 26 Jul 2021 13:39:00 EST http://www.broadcastmed.com/cancer/1411/news/immunotherapy-combination-shows-benefit-for-patients-with-advanced-melanoma-phase-3-trial-shows A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program. http://www.broadcastmed.com/cancer/1411/news/immunotherapy-combination-shows-benefit-for-patients-with-advanced-melanoma-phase-3-trial-shows Wed, 19 May 2021 13:31:00 EST http://www.broadcastmed.com/cancer/1411/news/in-landmark-study-an-arthritis-drug-appears-to-prevent-deadly-acute-graft-versus-host-disease-after-bone-marrow-transplant An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children鈥檚 Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA庐) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers. http://www.broadcastmed.com/cancer/1411/news/in-landmark-study-an-arthritis-drug-appears-to-prevent-deadly-acute-graft-versus-host-disease-after-bone-marrow-transplant Sat, 27 Mar 2021 12:53:00 EST http://www.broadcastmed.com/cancer/1411/news/first-fda-approval-of-car-t-cell-therapy-for-multiple-myeloma-marks-milestone-for-patients The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute. http://www.broadcastmed.com/cancer/1411/news/first-fda-approval-of-car-t-cell-therapy-for-multiple-myeloma-marks-milestone-for-patients Sat, 27 Mar 2021 08:03:00 EST http://www.broadcastmed.com/cancer/1411/news/dana-farber-to-offer-first-car-t-cell-therapy-for-indolent-follicular-lymphoma-following-fda-approval The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women鈥檚 Cancer Center (DF/BWCC) will be a certified treatment center for the therapy. http://www.broadcastmed.com/cancer/1411/news/dana-farber-to-offer-first-car-t-cell-therapy-for-indolent-follicular-lymphoma-following-fda-approval Mon, 08 Mar 2021 15:02:00 EST http://www.broadcastmed.com/cancer/1411/news/immunotherapy-combination-improves-outcomes-in-advanced-kidney-cancer An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients. http://www.broadcastmed.com/cancer/1411/news/immunotherapy-combination-improves-outcomes-in-advanced-kidney-cancer Wed, 03 Mar 2021 15:14:00 EST http://www.broadcastmed.com/cancer/9753/news/using-cbl0137-to-treat-patients-with-advanced-extremity-melanoma-or-sarcoma A central question in oncology is how to offer efficacious treatments while minimizing toxicity. This is especially true when treating advanced sarcoma and melanoma of the extremity. http://www.broadcastmed.com/cancer/9753/news/using-cbl0137-to-treat-patients-with-advanced-extremity-melanoma-or-sarcoma Mon, 01 Mar 2021 14:14:00 EST http://www.broadcastmed.com/dermatology/9753/news/identifying-neurotoxicity-earlier-in-car-t-cell-therapy At Roswell Park Comprehensive Cancer Center, Philip McCarthy, MD, Director of the Transplant and Cellular Therapy Center in the Department of Medicine, and a multidisciplinary team of colleagues recently undertook a study to understand how patients receiving CAR T-cell therapy were developing neurologic toxicity. http://www.broadcastmed.com/dermatology/9753/news/identifying-neurotoxicity-earlier-in-car-t-cell-therapy Thu, 25 Feb 2021 15:04:00 EST http://www.broadcastmed.com/cancer/1411/news/car-t-cell-therapy-generates-lasting-remissions-in-patients-with-multiple-myeloma In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found. http://www.broadcastmed.com/cancer/1411/news/car-t-cell-therapy-generates-lasting-remissions-in-patients-with-multiple-myeloma Wed, 24 Feb 2021 15:19:00 EST http://www.broadcastmed.com/pediatrics/1411/news/targeted-therapy-for-children-with-leukemia-can-provide-substantial-benefit-study-finds Testing tumor tissue for genetic alterations that can be targeted by drugs, a mainstay of treatment in a variety of cancers, can benefit many children with leukemia, investigators at Dana-Farber/Boston Children鈥檚 Cancer and Blood Disorders Center report in a new study. In some cases, such therapy can be lifesaving. http://www.broadcastmed.com/pediatrics/1411/news/targeted-therapy-for-children-with-leukemia-can-provide-substantial-benefit-study-finds Tue, 09 Feb 2021 15:20:00 EST http://www.broadcastmed.com/cancer/4561/news/response-and-prognosis-with-neoadjuvant-therapy-in-melanoma Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) http://www.broadcastmed.com/cancer/4561/news/response-and-prognosis-with-neoadjuvant-therapy-in-melanoma Mon, 08 Feb 2021 10:15:00 EST http://www.broadcastmed.com/cancer/1411/news/personalized-vaccine-produces-long-lasting-anti-tumor-response-in-patients-with-melanoma-study-shows Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women鈥檚 Hospital, and the Broad Institute of MIT and Harvard report in a new study. http://www.broadcastmed.com/cancer/1411/news/personalized-vaccine-produces-long-lasting-anti-tumor-response-in-patients-with-melanoma-study-shows Thu, 21 Jan 2021 14:04:00 EST http://www.broadcastmed.com/cancer/1106/news/new-procedure-provides-relief-for-thousands-of-prostate-cancer-patients-treated-with-radiation-therapy Other than skin cancer, prostate cancer is the most common cancer in American men, with more than 190,000 new cases diagnosed each year, according to the American Cancer Society. And each year, more than 60,000 American men opt to have their localized prostate cancer treated with high-dose radiation therapy. http://www.broadcastmed.com/cancer/1106/news/new-procedure-provides-relief-for-thousands-of-prostate-cancer-patients-treated-with-radiation-therapy Mon, 11 Jan 2021 16:46:00 EST http://www.broadcastmed.com/dermatology/1590/news/car-t-cell-therapy-now-available-at-fox-chase-for-relapsed-and-refractory-mantle-cell-lymphoma Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel (also known as TecartusTM), the first cell-based gene therapy approved by the Food and Drug Administration (FDA). http://www.broadcastmed.com/dermatology/1590/news/car-t-cell-therapy-now-available-at-fox-chase-for-relapsed-and-refractory-mantle-cell-lymphoma Sat, 09 Jan 2021 12:30:00 EST http://www.broadcastmed.com/dermatology/9753/news/roswell-park-experts-use-gene-sequencing-to-quantify-risk-of-skin-cancer-long-before-damage-is-visible New findings could lead to better tools for the identification of at-risk individuals, earlier cancer prevention. http://www.broadcastmed.com/dermatology/9753/news/roswell-park-experts-use-gene-sequencing-to-quantify-risk-of-skin-cancer-long-before-damage-is-visible Fri, 08 Jan 2021 11:00:00 EST http://www.broadcastmed.com/cancer/9753/news/new-car-t-cell-therapy-approved-and-available-at-roswell-park-for-lymphoma-patients Giving patients with relapsed or refractory mantle cell lymphoma (MCL) access to more treatment options, Roswell Park Comprehensive Cancer Center has been approved to administer the FDA-approved chimeric antigen receptor (CAR) T-cell therapy Tecartus. The immunotherapy drug is manufactured by Kite, a subsidiary of Gilead Sciences. http://www.broadcastmed.com/cancer/9753/news/new-car-t-cell-therapy-approved-and-available-at-roswell-park-for-lymphoma-patients Tue, 13 Oct 2020 21:52:00 EST http://www.broadcastmed.com/cancer/5225/news/sibley-memorial-hospital-offers-full-spectrum-of-leukemia-care The Johns Hopkins Kimmel Cancer Center in the greater Washington, D.C., area provides comprehensive leukemia care with access to clinical trials and Johns Hopkins鈥� hematopoietic stem cell transplant program, including haploidentical tranplant. http://www.broadcastmed.com/cancer/5225/news/sibley-memorial-hospital-offers-full-spectrum-of-leukemia-care Tue, 15 Sep 2020 11:30:00 EST http://www.broadcastmed.com/dermatology/5225/news/innovative-treatments-for-scars-from-burns-and-other-trauma Over the last decade, there have been dramatic advancements for patients with problematic scars from burns or other trauma. http://www.broadcastmed.com/dermatology/5225/news/innovative-treatments-for-scars-from-burns-and-other-trauma Thu, 30 Apr 2020 14:12:00 EST http://www.broadcastmed.com/cancer/9753/news/roswell-park-earns-distinction-for-cellular-immunotherapy-through-bluecross-blueshield As Roswell Park Comprehensive Cancer Center continues to utilize the latest immunotherapies that spell hope for so many of our patients, BlueCross BlueShield of Western New York has recognized us as a Blue Distinction Center for Cellular Immunotherapy 鈥� CAR-T (chimeric antigen receptor). http://www.broadcastmed.com/cancer/9753/news/roswell-park-earns-distinction-for-cellular-immunotherapy-through-bluecross-blueshield Fri, 03 Jan 2020 09:41:00 EST http://www.broadcastmed.com/cardiology/4561/news/car-t-cell-therapy-may-be-harnessed-to-treat-heart-disease Penn study finds immunotherapy reduces cardiac fibrosis and restores heart function in mice after cardiac injury http://www.broadcastmed.com/cardiology/4561/news/car-t-cell-therapy-may-be-harnessed-to-treat-heart-disease Wed, 11 Sep 2019 12:23:00 EST http://www.broadcastmed.com/gastroenterology/5225/news/johns-hopkins-developing-new-test-for-esophageal-cancer A Johns Hopkins gastroenterologist and a team of researchers use specific genetic biomarkers to detect dangerous changes in the cells that line the inside of the esophagus. 3D image shows concept model of esophageal cancer. http://www.broadcastmed.com/gastroenterology/5225/news/johns-hopkins-developing-new-test-for-esophageal-cancer Thu, 18 Apr 2019 16:10:00 EST http://www.broadcastmed.com/gastroenterology/5225/news/johns-hopkins-research-shows-potential-for-cure-for-polycystic-kidney-disease Working both with mice and with 3D models of kidney cysts, genetics researcher Liudmila Cebotaru found that introducing a specific CFTR corrector slowed cystic growth. http://www.broadcastmed.com/gastroenterology/5225/news/johns-hopkins-research-shows-potential-for-cure-for-polycystic-kidney-disease Thu, 18 Apr 2019 14:51:00 EST http://www.broadcastmed.com/cancer/7419/news/cancer-instagram Snapshot of immune system proteins predicts patients鈥� response to immunotherapy. http://www.broadcastmed.com/cancer/7419/news/cancer-instagram Fri, 30 Nov 2018 12:07:00 EST http://www.broadcastmed.com/cancer/5225/news/johns-hopkins-researchers-advance-role-of-circulating-tumor-dna-to-detect-early-melanoma-growth-uncover-treatment-options News & Publications November 26, 2018 http://www.broadcastmed.com/cancer/5225/news/johns-hopkins-researchers-advance-role-of-circulating-tumor-dna-to-detect-early-melanoma-growth-uncover-treatment-options Mon, 26 Nov 2018 11:20:00 EST http://www.broadcastmed.com/urology/5225/news/liquid-biopsy-and-personalized-treatment-for-bladder-cancer Discovery Winter 2019 http://www.broadcastmed.com/urology/5225/news/liquid-biopsy-and-personalized-treatment-for-bladder-cancer Mon, 05 Nov 2018 17:13:00 EST http://www.broadcastmed.com/urology/5225/news/in-bladder-cancer-the-subtype-matters Discovery Winter 2019 http://www.broadcastmed.com/urology/5225/news/in-bladder-cancer-the-subtype-matters Mon, 05 Nov 2018 16:58:00 EST http://www.broadcastmed.com/urology/5225/news/remembering-donald-s-coffey Discovery Winter 2019 http://www.broadcastmed.com/urology/5225/news/remembering-donald-s-coffey Sun, 04 Nov 2018 17:50:00 EST http://www.broadcastmed.com/cancer/5225/news/if-you-have-lymph-node-metastases-after-radical-prostatectomy-what-should-you-do Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/if-you-have-lymph-node-metastases-after-radical-prostatectomy-what-should-you-do Sun, 04 Nov 2018 17:37:00 EST http://www.broadcastmed.com/cancer/5225/news/not-so-many-biopsies-in-active-surveillance Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/not-so-many-biopsies-in-active-surveillance Sun, 04 Nov 2018 17:25:00 EST http://www.broadcastmed.com/cancer/5225/news/what-s-the-best-way-to-treat-localized-gleason-9-10-prostate-cancer Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/what-s-the-best-way-to-treat-localized-gleason-9-10-prostate-cancer Sat, 03 Nov 2018 17:59:00 EST http://www.broadcastmed.com/cancer/5225/news/new-device-extracts-ctcs-from-blood Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/new-device-extracts-ctcs-from-blood Sat, 03 Nov 2018 17:53:00 EST http://www.broadcastmed.com/cancer/5225/news/end-of-radiation-psa-and-intermediate-risk-cancer Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/end-of-radiation-psa-and-intermediate-risk-cancer Sat, 03 Nov 2018 17:47:00 EST http://www.broadcastmed.com/cancer/5225/news/prostate-cancer-therapy-and-the-gut-microbiome Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/prostate-cancer-therapy-and-the-gut-microbiome Sat, 03 Nov 2018 17:42:00 EST http://www.broadcastmed.com/cancer/5225/news/could-some-intermediate-risk-men-do-active-surveillance Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/could-some-intermediate-risk-men-do-active-surveillance Sat, 03 Nov 2018 17:29:00 EST http://www.broadcastmed.com/cancer/5225/news/psma-pet-data-system Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/psma-pet-data-system Sat, 03 Nov 2018 16:51:00 EST http://www.broadcastmed.com/urology/5225/news/thinking-about-cancer-in-new-ways Discovery Winter 2019 http://www.broadcastmed.com/urology/5225/news/thinking-about-cancer-in-new-ways Sat, 03 Nov 2018 16:46:00 EST http://www.broadcastmed.com/urology/5225/news/pain-control-after-radical-prostatectomy Discovery Winter 2019 http://www.broadcastmed.com/urology/5225/news/pain-control-after-radical-prostatectomy Sat, 03 Nov 2018 16:34:00 EST http://www.broadcastmed.com/cancer/5225/news/liver-fibrosis-and-psa Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/liver-fibrosis-and-psa Sat, 03 Nov 2018 15:24:00 EST http://www.broadcastmed.com/cancer/5225/news/custom-tailored-prostate-biopsy Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/custom-tailored-prostate-biopsy Sat, 03 Nov 2018 15:17:00 EST http://www.broadcastmed.com/cancer/5225/news/a-genetic-target-to-help-the-immune-system-fight-cancer Discovery Winter 2019 http://www.broadcastmed.com/cancer/5225/news/a-genetic-target-to-help-the-immune-system-fight-cancer Sat, 03 Nov 2018 15:04:00 EST http://www.broadcastmed.com/cancer/4561/news/blood-test-identifies-more-treatable-cancer-mutations-than-tissue-biopsy-alone Researchers from the Abramson Cancer Center of the University of Pennsylvania found that they could identify significantly more mutations through liquid biopsy instead of a solid tissue biopsy alone. http://www.broadcastmed.com/cancer/4561/news/blood-test-identifies-more-treatable-cancer-mutations-than-tissue-biopsy-alone Thu, 11 Oct 2018 19:53:00 EST http://www.broadcastmed.com/gastroenterology/5225/news/dna-and-protein-liquid-biopsy-finds-tumors-faster News Release December 2017 http://www.broadcastmed.com/gastroenterology/5225/news/dna-and-protein-liquid-biopsy-finds-tumors-faster Thu, 21 Dec 2017 11:52:00 EST http://www.broadcastmed.com/cancer/5225/news/phi-blood-test-spares-men-from-unneeded-biopsy Discovery January 01, 2017 http://www.broadcastmed.com/cancer/5225/news/phi-blood-test-spares-men-from-unneeded-biopsy Sun, 01 Jan 2017 22:35:00 EST